IN8BIO, INC. Logo

IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for cancer.

INAB | US

Overview

Corporate Details

ISIN(s):
US45674E1091
LEI:
Country:
United States of America
Address:
EMPIRE STATE BUILDING, 10118 NEW YORK

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Crinetics Pharmaceuticals, Inc. Logo
Develops oral therapeutics for endocrine diseases and endocrine-related tumors.
United States of America
CRNX
Develops drug delivery technology for localized chemotherapy in solid tumors.
Virgin Islands (British)
CRTX
CRISPR Therapeutics AG Logo
A gene-editing company developing gene-based medicines for serious diseases.
United States of America
CRSP
Crossject Logo
Develops emergency medications delivered via a needle-free auto-injector platform.
France
ALCJ
CSL Ltd. Logo
Global biotechnology company developing biotherapies, vaccines, and specialty medicines.
Australia
CSL
CS Medica A/S Logo
Develops and manufactures OTC medical devices and cosmetics containing cannabidiol.
Denmark
CSMED
CTC BIO, INC. Logo
Develops and manufactures human and animal health products using microbial fermentation.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops biologics to selectively modulate the immune system for cancer and autoimmune diseases.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
A clinical-stage biopharmaceutical company developing therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires, develops, and commercializes branded drugs for hospital and acute care.
United States of America
CPIX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.